
The OncoAlert 🚨 Coverage of #UromigosLIVE 🎸 2026 ctDNA: can we spare adjuvant EV? Dr. Jonathan Rosenberg 🇺🇸 @DrRosenbergMSK of @MSKCancerCenter discusses with Dr. Michiel van der Heijden🇳🇱 @MichvdHeijden of @NKI_nl on how he uses ctDNA in MIBC today: 🔹 Mostly post-op, based on IMvigor011: it helps risk-stratify patients, especially after an excellent pathologic response to neoadjuvant therapy 🔹 Rising ctDNA before surgery is a very bad sign. Consider other approaches before cystectomy 🔹 Clear before surgery, negative after and staying negative: these patients do really, really well 🔹 Bladder preservation cuts both ways. Persistently positive patients likely fail distantly, but some clear their ctDNA with surgery. Would they also clear with chemoradiation or more EV-P? EV-209, EV-309 and sac-TMT + pembro trials should help answer this 🔹 ctDNA down but not cleared → go to surgery, then continue adjuvant therapy 💬 "Surgery is curing patients. It's just not curing all patients." 💡 After VOLGA, he's more likely to drop adjuvant EV: great neoadjuvant response + ctDNA-negative after surgery → most are probably cured. Less EV means less toxicity, and some of it is long-term. Would you de-escalate adjuvant EV based on ctDNA? 👇 #BladderCancer #MIBC #ctDNA #GUOnc @Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan




























